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Background
To describe the prevalence and risk factors for hyper-
sensitivity reactions (HSR) to biologic disease modifying
antirheumatic drugs (bDMARD) from the TTSH Singa-
pore Biologics Registry.
Methods
Consecutive patients who had ever received a bDMARD
were followed up during the study period 1 January
2001 to 31 December 2013.
Results
There were 217 patients of Asian ethnicity who had ever
received a bDMARD, of whom 30 (13.8%) had received
more than 1 bDMARD. These comprised rituximab (78,
35.9%), infliximab (59, 27.2%), etanercept (51, 23.5%),
adalimumab (41, 18.9%), golimumab (8, 3.7%), anakinra
(4, 1.8%), abatacept and tocilizumab (3, 1.4% each). HSR
occurred in 4 female patients following previous expo-
sure to an anti-tumour necrosis factor inhibitor (TNFi)
(2) and rituximab (2) respectively. A 67-year-old Chinese
female with rheumatoid arthritis developed fever and
hypotension without rash or other organ-specific involve-
ment, within 1 hour of the second dose of infliximab
200 mg 2 weeks later. She switched to adalimumab with-
out adverse reaction. Another 34-year-old Malay female
with psoriatic arthritis developed optic neuritis following
the third dose of adalimumab 40 mg every other week.
She recovered and switched to abatacept without adverse
reaction. A 28-year-old female with systemic lupus
erythematosus (SLE) developed acute urticaria following
the second dose of the third course of rituximab 500 mg
given 2 weeks apart. Another 27-year old female with
SLE developed anaphylaxis with flushing, facial angioe-
dema, dyspnoea and wheeze, following the second dose
of the second course of rituximab 500 mg 5 years later.
None of the patients with immediate reactions to inflixi-
mab/ rituximab agreed to have diagnostic skin testing in
view of costs. The patient with anaphylaxis declined
desensitization to rituximab. There were no HSR to any
of the other bDMARDs. Exposure to more than 1
bDMARD within/across different classes did not increase
the risk of HSR. There were no deaths from HSR.
Conclusion
HSR to bDMARDs is uncommon in our cohort. Risk
factors include repeated dosing, but not exposure to
more than 1 bDMARD within/across different classes.
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